The biopharmaceutical sector got slammed in early February by an unexpected market correction when the Dow plummeted 1,175 points in a single day, the largest single points drop on record. The market did, however, get off the mat and recover some of its losses as the month rolled on, but it remained susceptible to any negative economic or financial news and often tumbled hundreds of points in a single day following such announcements.